Hurtado MR, Vicente HB, Sarre ÁD, Vargas VP, Candelaria HM, Rojas SM, Best ACR, Cruz VJ

Language: Spanish
References: 32
Page: 204-208
PDF size: 261.84 Kb.

ABSTRACT

Introduction: The accelerated phase is a condition of progression of the CML. Our first line of treatment is imatinib mesylate (IM); however, there is no information on long-term outcomes in AP. Material and methods: We conducted a retrospective comparative study of patients with CML Ph+. Patients with CP received IM 400 mg/day and patients with AP 600 mg/day, both were followed with cytogenetic studies with fluorescence in situ hybridization (FISH) (minimum 200 nuclei analyzed) every three months. Results: The median time for the complete cytogenetic response (CCyR) was eight months in CP and 12 months in AP. The length of this response in CP was 73 months in 100% of patients and 30 months in 42.9% of AP. The median survival (follow-up of 120 months) was 70 months in AP and 150 months in CP (p ‹ 0.0001). The median long-term free-disease and overall survival was 73 months in CP and 30 months in AP. Conclusions: The AP has lower CCyR and survival, which suggests the need to change the initial treatment.

REFERENCES

1. Vicente-Hernández B, Hurtado-Monroy R, Sarre-Álvarez D, Vargas-Viveros P, Rojas M, Best C et al. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia Philadelphia + (CML-Ph+) in accelerated phase (AP), comparison with chronic phase. A long-term retrospective study. Clin Lymphoma, Myeloma & Leukemia. 2016; 16 (Suppl. 2); s54-s55.

2. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and responses in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2016; 103 (8): 2794-2799.

3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96 (10): 3343-3356.

4. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016; 91 (2): 252-265.

5. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014; 64 (1): 9-29.

6. Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. ASH Education Book. 2011; 2011 (1): 128-135.

7. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007; 357 (3): 258-265.

8. Cortes JE, Talpaz M, O’Brien S, Faderl S, García-Manero G, Ferrajoli A et al. Staging of chronic myeloid leukemia in the Imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006; 106 (6): 1306-1315.

9. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014; 14 (2): 155-162.

10. Mukherjee S, Kalaycio M. Accelerated phase CML: outcomes in newly diagnosed vs. progression from chronic phase. Curr Hematol Malig Rep. 2016; 11 (2): 86-93.

11. Kantarjian HM, O’Brien S, Cortes JE, Smith TL, Ríos MB, Shan J et al. Treatment of Philadelphia chromo-some-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002; 8 (7): 2167-2176.

12. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986; 314 (17): 1065-1069.

13. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al. Survival advantage from imatinib compared with the combination interferon-alfa plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006; 108 (5): 1478-1484.

14. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Am Soc Hematol Educ Program. 2011; 2011: 121-127.

15. Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012; 2012 (1): 115-121.

16. Cornelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimized adherence in patients with chronic myeloid leukemia: the role of the mid-level practitioner. J Support Oncol. 2012; 10 (1): 14-24.

17. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006; 91 (4): 513-521.

18. Eiring A, Khorashad J, Morley K, Deininger MW. Advances in the treatment of chronic myeloid leukemia. BMC Med. 2011; 9: 99.

19. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346 (9): 645-652.

20. Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelo-genous leukemia treatment. Ann Hematol. 2015; 94 (2): 123-131.

21. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European leukemia net recommendations for the management of the chronic myeloid leukemia. Blood. 2013: 122 (6): 872-884.

22. Alikian M, Gale P, Apperley J, Foroni L. Molecular techniques for the personalized management of patients with chronic myeloid leukaemia. Biomol Detect Quantif. 2017; 11: 4-20.

23. Shanmuganathan N, Hiwase DK, Ross D. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leuk Lymphoma. 2017; 58 (12): 2799-2810.

24. Kantarjian H, Talpaz M, O’Brien S, Giles F, Faderl S, Verstovsek S et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. Cancer. 2005; 103 (10): 2099-2108.

25. Capdeville R, Krahnke T, Hatfield A, Ford JM, Van Hoomissen I, Gathmann I. Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Ann Oncol. 2008 (19): 1320-1326.

26. Schiffer CA. BCR-ABL Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007; 357(3): 258-265.

27. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia. Results of a phase 2 study. Blood. 2002; 99 (6): 1928-1937.

28. Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26 (10): 2172-2175.

29. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain and for expressing results. Blood. 2006: 108 (1): 28-37.

30. Lang T, Sesic M. How to report statistics in medicine: annotated guidelines for authors, editors and reviewers. 2nd ed. Philadelphia. American College of Physicians. 2006, pp. 115-124.

31. Kantarjian H, O’Brien S, Jabbour E, García-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single institution historical experience. Blood. 2012; 119 (9): 1981-1987.

32. Thota NK, Gundeti S, Linga VG, Coca P, Tara RP, Raghunadharao. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis. Indian J Cancer. 2014; 51 (1): 5-9.